MEP Amplitudes and Stimulation Intensity (%MSO) Before and After Substance Administration
| . | . | MEP Amplitude (mV) . | %MSO . | |||
|---|---|---|---|---|---|---|
| tDCS . | Medication . | Baseline 1 . | Baseline 2 . | Baseline 3 . | Baseline 1 . | Baseline 3 . |
| Sham | Placebo | 0.97 ± 0.05 | 0.97 ± 0.13 | 1.01 ± 0.08 | 53.25 ± 11.01 | 53.25 ± 11.01 |
| Anodal | Placebo | 1.01 ± 0.49 | 1.06 ± 0.19 | 1.00 ± 0.07 | 53.70 ± 7.44 | 53.58 ± 7.40 |
| CIT 20 mg | 0.97 ± 0.06 | 1.02 ± 0.45 | 0.97 ± 0.06 | 53.33 ± 10.31 | 53.20 ± 10.83 | |
| CIT 40 mg | 1.00 ± 0.07 | 1.18 ± 0.36 | 1.01 ± 0.09 | 53.79 ± 8.51 | 53.04 ± 8.62 | |
| Cathodal | Placebo | 1.00 ± 0.84 | 1.07 ± 0.38 | 0.97 ± 0.07 | 52.00 ± 9.65 | 51.45 ± 9.82 |
| CIT 20 mg | 1.01 ± 0.09 | 1.12 ± 0.24 | 1.01 ± 0.04 | 52.33 ± 9.20 | 51.79 ± 9.15 | |
| CIT 40 mg | 0.98 ± 0.07 | 1.19 ± 0.38 | 1.01 ± 0.08 | 51.33 ± 10.33 | 51.04 ± 9.62 | |
| . | . | MEP Amplitude (mV) . | %MSO . | |||
|---|---|---|---|---|---|---|
| tDCS . | Medication . | Baseline 1 . | Baseline 2 . | Baseline 3 . | Baseline 1 . | Baseline 3 . |
| Sham | Placebo | 0.97 ± 0.05 | 0.97 ± 0.13 | 1.01 ± 0.08 | 53.25 ± 11.01 | 53.25 ± 11.01 |
| Anodal | Placebo | 1.01 ± 0.49 | 1.06 ± 0.19 | 1.00 ± 0.07 | 53.70 ± 7.44 | 53.58 ± 7.40 |
| CIT 20 mg | 0.97 ± 0.06 | 1.02 ± 0.45 | 0.97 ± 0.06 | 53.33 ± 10.31 | 53.20 ± 10.83 | |
| CIT 40 mg | 1.00 ± 0.07 | 1.18 ± 0.36 | 1.01 ± 0.09 | 53.79 ± 8.51 | 53.04 ± 8.62 | |
| Cathodal | Placebo | 1.00 ± 0.84 | 1.07 ± 0.38 | 0.97 ± 0.07 | 52.00 ± 9.65 | 51.45 ± 9.82 |
| CIT 20 mg | 1.01 ± 0.09 | 1.12 ± 0.24 | 1.01 ± 0.04 | 52.33 ± 9.20 | 51.79 ± 9.15 | |
| CIT 40 mg | 0.98 ± 0.07 | 1.19 ± 0.38 | 1.01 ± 0.08 | 51.33 ± 10.33 | 51.04 ± 9.62 | |
CIT = citalopram, MEP = motor evoked potential, %MSO = percentage of maximal stimulator output – the stimulation intensity, mV = milivolts, tDCS = transcranial direct current stimulation.
Baseline 1 refers to the MEP measured at the beginning of each session, baseline 2 refers to the MEP measured 1 hour and 45 minutes after medication intake, and baseline 3 refers to the MEP measurement immediately conducted after baseline 2 if transcranial magnetic stimulation intensity adjustment was necessary. Data are presented as mean ± standard deviation.
MEP Amplitudes and Stimulation Intensity (%MSO) Before and After Substance Administration
| . | . | MEP Amplitude (mV) . | %MSO . | |||
|---|---|---|---|---|---|---|
| tDCS . | Medication . | Baseline 1 . | Baseline 2 . | Baseline 3 . | Baseline 1 . | Baseline 3 . |
| Sham | Placebo | 0.97 ± 0.05 | 0.97 ± 0.13 | 1.01 ± 0.08 | 53.25 ± 11.01 | 53.25 ± 11.01 |
| Anodal | Placebo | 1.01 ± 0.49 | 1.06 ± 0.19 | 1.00 ± 0.07 | 53.70 ± 7.44 | 53.58 ± 7.40 |
| CIT 20 mg | 0.97 ± 0.06 | 1.02 ± 0.45 | 0.97 ± 0.06 | 53.33 ± 10.31 | 53.20 ± 10.83 | |
| CIT 40 mg | 1.00 ± 0.07 | 1.18 ± 0.36 | 1.01 ± 0.09 | 53.79 ± 8.51 | 53.04 ± 8.62 | |
| Cathodal | Placebo | 1.00 ± 0.84 | 1.07 ± 0.38 | 0.97 ± 0.07 | 52.00 ± 9.65 | 51.45 ± 9.82 |
| CIT 20 mg | 1.01 ± 0.09 | 1.12 ± 0.24 | 1.01 ± 0.04 | 52.33 ± 9.20 | 51.79 ± 9.15 | |
| CIT 40 mg | 0.98 ± 0.07 | 1.19 ± 0.38 | 1.01 ± 0.08 | 51.33 ± 10.33 | 51.04 ± 9.62 | |
| . | . | MEP Amplitude (mV) . | %MSO . | |||
|---|---|---|---|---|---|---|
| tDCS . | Medication . | Baseline 1 . | Baseline 2 . | Baseline 3 . | Baseline 1 . | Baseline 3 . |
| Sham | Placebo | 0.97 ± 0.05 | 0.97 ± 0.13 | 1.01 ± 0.08 | 53.25 ± 11.01 | 53.25 ± 11.01 |
| Anodal | Placebo | 1.01 ± 0.49 | 1.06 ± 0.19 | 1.00 ± 0.07 | 53.70 ± 7.44 | 53.58 ± 7.40 |
| CIT 20 mg | 0.97 ± 0.06 | 1.02 ± 0.45 | 0.97 ± 0.06 | 53.33 ± 10.31 | 53.20 ± 10.83 | |
| CIT 40 mg | 1.00 ± 0.07 | 1.18 ± 0.36 | 1.01 ± 0.09 | 53.79 ± 8.51 | 53.04 ± 8.62 | |
| Cathodal | Placebo | 1.00 ± 0.84 | 1.07 ± 0.38 | 0.97 ± 0.07 | 52.00 ± 9.65 | 51.45 ± 9.82 |
| CIT 20 mg | 1.01 ± 0.09 | 1.12 ± 0.24 | 1.01 ± 0.04 | 52.33 ± 9.20 | 51.79 ± 9.15 | |
| CIT 40 mg | 0.98 ± 0.07 | 1.19 ± 0.38 | 1.01 ± 0.08 | 51.33 ± 10.33 | 51.04 ± 9.62 | |
CIT = citalopram, MEP = motor evoked potential, %MSO = percentage of maximal stimulator output – the stimulation intensity, mV = milivolts, tDCS = transcranial direct current stimulation.
Baseline 1 refers to the MEP measured at the beginning of each session, baseline 2 refers to the MEP measured 1 hour and 45 minutes after medication intake, and baseline 3 refers to the MEP measurement immediately conducted after baseline 2 if transcranial magnetic stimulation intensity adjustment was necessary. Data are presented as mean ± standard deviation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
